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De novo or acquired resistance to endocrine therapy limits its utility in a significant number of estrogen
receptor-positive (ER-positive) breast cancers. It is crucial to identify novel targets for therapeutic intervention
and improve the success of endocrine therapies. Splicing factor 3b, subunit 1 (SF3B1) mutations are described
in luminal breast cancer albeit in low frequency. In this study, we evaluated the role of SF3B1 and SF3B3, critical
parts of the SF3b splicing complex, in ER-positive endocrine resistance. To ascertain the role of SF3B1/SF3B3
in endocrine resistance, their expression levels were evaluated in ER-positive/endocrine-resistant cell lines
(MCF-7/LCC2 and MCF-7/LCC9) using a real-time quantitative reverse transcription PCR (qRT-PCR). To further
determine their clinical relevance, expression analysis was performed in a cohort of 60 paraffin-embedded
ER-positive, node-negative breast carcinomas with low, intermediate, and high Oncotype DX recurrence scores.
Expression levels of SF3B1 and SF3B3 and their prognostic value were validated in large cohorts using publicly
available gene expression data sets including The Cancer Genome Atlas. SF3B1 and SF3B3 levels were
significantly increased in ERa-positive cells with acquired tamoxifen (MCF-7/LCC2; both Po0.0002) and
fulvestrant/tamoxifen resistance (MCF-7/LCC9; P¼ 0.008 for SF3B1 and P¼ 0.0006 for SF3B3). Expression levels
of both MCF-7/LCC2 and MCF-7/LCC9 were not affected by additional treatments with E2 and/or tamoxifen.
Furthermore, qRT-PCR analysis confirmed that SF3B3 expression is significantly upregulated in Oncotype DX
high-risk groups when compared with low risk (P¼ 0.019). Similarly, in publicly available breast cancer gene
expression data sets, overexpression of SF3B3, but not SF3B1, was significantly correlated with overall survival.
Furthermore, the correlation was significant in ER-positive, but not in ER-negative tumors.This is the first study to
document the role of SF3B3 in endocrine resistance and prognosis in ER-positive breast cancer. Potential
strategies for therapeutic targeting of the splicing mechanism(s) need to be evaluated.
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The process of alternative splicing results in synth-
esis of multiple mRNA variants from a single gene.
Earlier studies reported the importance of splice
variants in a number of key genes regulating signal-
ing pathways such as apoptosis, metabolism, and
angiogenesis. Alterations in expression of some
splicing factors, genes that regulate splicing process
of mature messenger RNA species from primary
transcripts, have also been reported in various
cancers including breast cancer.1 The utilization
of next-generation sequencing technologies have
further revealed the presence of somatic mutations
in splicing factors.2 Among them, the SF3B1
mutations occurred in several types of hemato-
logical malignancies as well as in solid cancers,
such as breast, pancreatic cancers, and uveal
melanomas.3–7 These mutations were shown to be
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associated with alternative splicing in lymphocytic
leukemia and uveal melanomas.8,9 However, the
impact of these factors in the clinical setting has not
been well established in breast cancer, and their
clinical utility is not clear.
SF3B1 is one of the 35 most frequently mutated
genes using next-generation sequencing on 510
breast tumors.5 However, the frequency is low (2%
of all tumors). Of the 15 nonsilent mutations, the
majority were missense mutations. Patients with
estrogen receptor (ER)-positive and HER2 subtypes
harbored the majority of these mutations. The SF3B1
was also among the 18 significantly mutated genes
in untreated ER-positive breast tumors from 77
patients accrued from two neoadjuvant aromatase
inhibitor clinical trials.10 Taken together, these
studies indicate the potential role of SF3B multi-
protein complex in ER-positive breast cancers.
SF3B1 encodes the largest subunit of the SF3B
protein complex, a key component of the core
spliceosome complex essential for the accurate
excision of introns from pre-mRNA to form mature
mRNA. SF3B1 interacts with other SF3B subunits
including SF3B3.11–14 Based on the pre-
clinical data, SF3B1 mutation (R1074H) confers
resistance to spliceosome inhibitors, such as pladi-
enolide, and impairs its binding to SF3B complex.15
Furthermore, SF3B1 and SF3B3 interactions are
believed to be necessary to form a binding site for
this class of inhibitors.15,16 Therefore, these genes
may serve as potential new therapeutic targets in
ER-positive breast cancer. However, there is a
relative lack of data regarding the expression and
prognostic value of these genes in ER-positive breast
cancer and their clinical utility in endocrine
therapy. Despite the presence of SF3B1 mutations,
no SF3B3 mutations were detected in either The
Cancer Genome Atlas (TCGA) or in neoadjuvant
aromatase inhibitor clinical trials. Decreased SF3B3
expression has been reported in breast cancer, but
attributed to loss of 16q, the location of the gene.17
In this study, the expression of SF3B1 and SF3B3
was analyzed in breast cancer cell lines with
acquired resistance to endocrine therapy and in a
cohort of Oncotype DX cases using real-time
quantitative reverse transcription PCR (qRT-PCR).
The findings were further confirmed in publicly
available breast cancer data sets, including TCGA,
and correlated their prognostic relevance and clinical
utility for endocrine therapy. Here, we report the
clinical relevance of SF3B1 and SF3B3 in develop-
ment of innate and acquired endocrine resistance in
ER-positive breast cancers.
Materials and methods
Breast Cancer Cell Lines
LCC2 (MCF-7/LCC2; resistant to tamoxifen), LCC9
(MCF-7/LCC9; resistant to fulvestrant (Faslodex; ICI
182,780) and cross-resistant to tamoxifen), and AZ
(MCF-7/AZ control) cell lines were kind gifts from
Dr R. Clarke (Georgetown University Medical School,
Washington DC).18,19 Cell lines have been carefully
maintained in a humidified tissue culture incubator
at 37 1C in 5% CO2:95% air atmosphere and stocks
of the earliest passage cells have been stored.
The cell lines were grown in phenol-red–free
DMEM containing 5% charcoal-stripped fetal calf
serum and 100mg/ml penicillin as described
previously.18,19
Oncotype DX Samples
All protocols were reviewed and approved by the
Institutional Review Board of Indiana University.
Sixty archival formalin-fixed, paraffin-embedded
tumor blocks were obtained from patients with
ER-positive (4 1% expression as per ASCO-CAP
guidelines) node-negative breast carcinomas at
the Indiana University Simon Cancer Center based
on their Oncotype DX recurrence score (19 low
score, 21 intermediate score, and 20 high score).
Four of the 60 cases had a lobular histology.
Demographic and clinical characteristics of the
patients were acquired from medical charts
(Supplementary Table S1).
RNA Isolation and qRT-PCR
RNA was extracted from 10mm-thick sections of
archival paraffin blocks using RecoverAll total
nucleic acid isolation kit (Life Technologies, Grand
Island, NY, USA). For breast cancer cell lines, RNAs
were isolated (RNeasy isolation kit, Qiagen, VA,
USA) and treated with Turbo DNase (Ambion, Foster
City, CA, USA) to remove contaminating DNA. The
quality of RNA was assessed using the Nanodrop
ND-1000 spectrophotometer (ThermoScientific,
Wilmington, DE, USA). Total RNAs were reverse-
transcribed using the high capacity cDNA reverse
transcription kit (Life Technologies) according
the manufacturer’s instructions. The mRNA levels
of SF3B1 and SF3B3 were analyzed by qRT-PCR
using TaqMan gene expression assays on an ABI
Prism 7900 platform (Applied Biosystems, Foster
City, CA, USA) with ACTB and GUSB as endogen-
ous controls for normalization. All qRT-PCR
reactions from tumor blocks and breast cancer cell
lines were performed in duplicates and triplicates,
respectively. The relative quantification of the
gene expression changes (fold) was analyzed accord-
ing to DDCt method using the Applied Biosystems
DataAssist software v3.0. For qRT-PCR statistical
analysis, Applied Biosystems DataAssist software
v3.0 was performed and all graphs were generated
using GraphPad Prism 5 software. The error
bars were calculated and represented in terms of
mean s.d.
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Analysis Using TCGA Database
To validate the clinical relevance of SF3B1 and
SF3B3 levels in larger cohorts, we obtained the
normalized expression levels of SF3B1 and SF3B3
(level 3 data) in breast cancer patients enrolled in
the TCGA breast invasive carcinoma study with
subtype classification (available at http://tcga-data.
nci.nih.gov/tcga/tcgaHome2.jsp). Patients with
breast cancer were categorized as having one of four
different subtypes (luminal A, luminal B, HER2-
enriched, or basal) based on the PAM50 signature.
The expression of SF3B1 and SF3B3 in all
four subtypes was obtained and compared with
luminal A breast tumors. The significance of
change in expression of each subtype from that
of the luminal A cohort was estimated using
Wilcox test.
The clinical information for each patient was also
obtained. To model survival, gene expression at or
below 33rd percentile was considered low, at or
above 67th percentile was considered high, and
those falling within the 33rd and 67th percentile
were considered medium. Overall survival was
calculated from the date of initial diagnosis of breast
cancer to disease-specific death (patients whose
vital status is termed dead) and months to last
follow up (for patients who are alive). Kaplan–Meier
survival analysis was used to estimate association of
the gene’s expression with survival of patients. The
‘survival’ package in R (R Foundation for Statistical
Computing) was used for statistical analyses. An
analysis of relapse-free survival was not possible in
TCGA data set.
Analysis of Publicly Available Data Sets
SF3B1 and SF3B3 expression levels were analyzed
based on ER status, molecular subtypes, and other
clinicopathological parameters using the data sets
from the gene expression-based outcome for breast
cancer online algorithm (GOBO).20 GOBO is a
web-based analysis tool that utilizes 11 publicly
available Affymetrix U133A gene expression data
curated from 1881 breast cancer patients with
associated stage, grade, nodal status, and intrinsic
molecular classification.21 Of all 1881 tumors, the
groups were distributed as follows: (1) ER-positive
tumors (n¼ 1225), (2) ER-negative tumors (n¼ 395),
(3) systemically untreated patients (n¼ 927), and (4)
patients treated with tamoxifen alone (n¼ 326).
Clinical characteristics of individual data sets were
described previously.20 Association of outcome was
investigated for each patient cohort with relapse-
free survival or overall survival as end points and
10-year censoring in the above groups. The Kaplan–
Meier survival analysis was calculated using
Cox proportional hazard model, and the score test
of the proportional hazard model is equivalent to the
log-rank test.
Results
SF3B1 and SF3B3 Are Upregulated in Acquired
Endocrine Resistance Models
To further determine the relevance of the identified
genes in endocrine resistance, we analyzed the
relative expression levels of these genes in a
panel of endocrine-resistant, ER-positive breast
cancer cell lines using qRT-PCR. SF3B1 and SF3B3
expression levels were significantly upregulated in
LCC2 cells compared to control cells (AZ). (fold
change: 5.30; P¼ 0.0002 and fold change: 4.012;
P¼ 0.0002, respectively) (Figure 1). LCC9 cells also
exhibited significant upregulation for SF3B1 (fold
change: 2.92; P¼ 0.0008) and SF3B3 (fold
change: 3.58; P¼ 0.0006). Interestingly, SF3B1 and
SF3B3 levels did not change in response to
E2 alone, tamoxifen alone, or E2 and tamoxifen
treatment in combination, indicating that their
Figure 1 Expression levels of SF3B1 and SF3B3 in tamoxifen-
resistant LCC2 (MCF-7/LCC2), fulvestrant and tamoxifen-cross-
resistant LCC9 (MCF-7/LCC2), and control sensitive cell line
(MCF-7/AZ) using real-time quantitative reverse transcription
PCR assay; vehicle (ethanol), E2 (b-estradiol:10 10 M), tamoxifen
(4-OH-Tam:10 6 M), or in combination with E2 and tamoxifen.
*Po0.05; statistically significant.
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upregulation is independent of E2 stimulation.
These findings suggest the importance of elevated
expression of SF3B1 and SF3B3 in endocrine
resistance and the likelihood of recurrence of
ER-positive breast cancer.
SF3B3 Is Significantly Upregulated in Cases with
Oncotype DX High-Recurrence Scores
The Oncotype DX recurrence score in current
practice predicts the likelihood of distant recurrence
in tamoxifen-treated patients with node-negative,
ER-positive breast cancer.22 Furthermore, analysis of
the National Surgical Adjuvant Breast and Bowel
Project B14 clinical trial has shown that patients
with high-recurrence score have innate resistance to
tamoxifen. However, the assay does not provide the
mechanistic basis for endocrine resistance. As
tamoxifen resistance might contribute to early
recurrence, we first decided to determine the
expression levels of SF3B1 and SF3B3 in a cohort of
60 paraffin-embedded ER-positive, node-negative
breast carcinomas with low, intermediate, and high
(19, 21, and 20 cases, respectively) recurrence scores.
qRT-PCR analysis revealed that expression of SF3B3
was upregulated in cases with high-recurrence scores
compared with the low-recurrence score cases (fold
change: 2.44-fold; P¼ 0.019) (Figure 2). However,
expression of SF3B1 was slightly increased and did
not reach statistical significance (fold change: 1.26-
fold). Expression of SF3B1 and SF3B3 remained
nonsignificant in cases with intermediate score
compared with cases with low scores being 0.90-fold
and 1.21-fold, respectively. These results suggest that
high expression of SF3B3may indicate the likelihood
of high recurrence and might contribute to endocrine
resistance in ER-positive cancers.
Validation of SF3B3 Expression Using Specimens
from TCGA and Affymetrix Data Sets of Breast Cancer
To assess the correlation of SF3B3 expression in
larger cohorts of breast cancer, we analyzed the data
of breast tumors from TCGA that can categorize
the samples to PAM50 subtypes.5 The expression
of SF3B3 was higher in luminal B (n¼ 290;
P¼ 7.59e 12), HER2 (n¼ 102; P¼ 7.586e 19),
and basal (n¼ 166; P¼ 1.66e 51) subtypes when
compared with luminal A (n¼ 366) (Figure 3a),
suggesting that the expression of SF3B3 correlated
positively with the aggressiveness of subtypes.
Luminal A tumors exhibited the lowest SF3B3
expression, while the sequential order of increase
was observed in luminal B, HER2, and basal subtype
being the highest (Figure 3a).
Expression of SF3B3 was also assessed using data
from GOBO for all breast cancer tumors (n¼ 1881).20
SF3B3 expression was significantly lower in ER-
positive tumors (n¼ 1225) compared with ER-
negative (n¼ 395; Po0.00001) (Figure 3b). Using
the PAM50 subtypes (Figure 3c), the expression
levels were higher in the order of luminal B
(n¼ 471), HER2 (n¼ 240), and basal subtype
(n¼ 304) being the highest, consistent with TCGA
expression data. SF3B3 expression also correlated
positively with higher grade having positive asso-
ciation with grade 3 cases (n¼ 239 for grade 1,
n¼ 677 for grade 2, and n¼ 495 for grade 3)
(Supplementary Figure S1).
We also analyzed the levels of SF3B1 expression
in TCGA and Affymetrix data sets. In TCGA, SF3B1
levels did not reach statistical significance in
luminal B and HER2 in comparison with luminal
A tumors. SF3B1was significantly decreased only in
basal subtype (P¼ 0.04) when compared with
luminal A (Supplementary Figure S2A). Consistent
with this observation, SF3B1was significantly lower
in ER-negative tumors compared with ER-positive
tumors in Affymetrix data sets (Po0.00001)
(Supplementary Figure S2B), with highest expres-
sion in luminal A; whereas, its expression was
lower in luminal B, HER2, and basal subtypes
(Supplementary Figure S2C). On the other hand,
high expression of SF3B1 is associated with grade 1
(Supplementary Figure S2D). These results suggest a
differential role for SF3B1 and SF3B3 in breast
cancer.
Figure 2 Expression of SF3B1 and SF3B3 in patients with estrogen receptor-positive tumors using real-time quantitative reverse
transcription PCR assay. The expression of SF3B1 and SF3B3 is higher in patients with high-recurrence scores; LS, low score; IS,
intermediate score; HS, high score in Oncotype DX. *P¼0.019; statistically significant.
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High Expression of SF3B3 Correlates with Poor
Prognosis in Patients with ER-Positive Breast Cancer
We next analyzed the correlation of SF3B1 and
SF3B3 expression with overall survival using TCGA
data of breast cancer subjects. The expression of
SF3B3 in these subjects was categorized in three
quantiles based on low (n¼ 324; black line), medium
(n¼ 314; light gray line), and high (n¼ 314; dark gray
line) expressions (Figure 4a). The higher SF3B3
expression was associated with shorter overall
survival compared with lower expression in breast
cancer patients (P¼ 0.00461). In a cohort with high
SF3B3 levels, the overall survival probability was
79.6% and 47.0% at 50 and 100 months, respec-
tively, and those with low SF3B3 levels showed a
survival probability of 90.4% and 67.4% at 50 and
100 months, respectively. On the other hand, SF3B1
levels were not associated with survival (high
SF3B1, 82.8% and 46.9% at 50 and 100 months
versus low SF3B1, 87.9% and 58.6% for 50 and 100
months, respectively) (Supplementary Figure S3a).
We further assessed the correlation of SF3B3
expression with overall survival and relapse-free
survival in various categories including ER status,
and tamoxifen-treated cases representative of 11 micro-
array data sets using the GOBO tool (Figures 4b and c).
High expression of SF3B3 was associated with shorter
overall survival in all tumors (P¼ 1e 05) and in ER-
positive tumors (P¼ 1e 05), but not in ER-negative
tumors (Figure 4b). Higher expression of SF3B3 was
also associated with relapse-free survival in all
tumors (P¼ 0.00001) and in ER-positive tumors
(P¼ 2e 05) (Figure 4c). Significant association of
poor relapse-free survival and high SF3B3 was also
observed in ER-positive tamoxifen-treated popula-
tion (P¼ 0.02573). Consistent with overall survival,
the expression levels were not associated with
relapse-free survival in ER-negative tumors.
Correlation of high SF3B3 expression with shorter
overall survival stayed significant for other para-
meters (all tumors: node-negative; P¼ 0.00551 and
node-positive; P¼ 0.00093) (Supplementary Figure
S3b). SF3B3 was also significantly correlated
with relapse-free survival for these parameters
(all tumors: node-negative; P¼ 0.01679 and node-
positive; P¼ 8e 05). In ER-positive tumors, node-
negative tumors were more significantly associated
with high SF3B3 (Supplementary Figure S3c).
Analysis of SF3B3 expression with clinical vari-
ables showed that low SF3B3 levels and node-
negative tumors were significantly associated with
better overall survival (hazard ratio (HR)¼ 0.46;
95% CI¼ 0.33–0.64; P¼ 3.838e 06) and relapse-
free survival (HR¼ 0.72; 95% CI¼ 0.54–0.96;
P¼ 0.0266) compared with node-positive tumors
(Tables 1 and 2). On the other hand, HR for larger
tumors (420mm) was significantly high for overall
survival (HR¼ 1.94; 95% CI¼ 1.38–2.72; P¼ 0.0001)
and for relapse-free survival (HR¼ 1.92; 95%
CI¼ 1.45–2.54; P¼ 5.388e 06), being a significant
factor for survival and relapse. Age (450) stayed
significant for overall survival (HR¼ 1.58; 95%
CI¼ 1.11–2.24; P¼ 0.0117), but not relapse-free
survival. Grade was not significantly associated
with either overall survival or relapse-free survival
in multivariable analysis. No significant correlation
was observed for SF3B1 expression with overall
survival and/or relapse-free survival or in any
categories in both TCGA and Affymetrix data sets
in GOBO analysis (data not shown). These results
further validate the involvement of high expression
of SF3B3 with poor prognosis using large cohorts of
breast cancer and its potential contribution to
endocrine resistance in ER-positive cancers.
Discussion
ER-positive subtype constitutes 65–70% of all breast
cancers. ER expression is a strong predictive
factor for efficacy of endocrine therapy. Although
Figure 3 SF3B3 expression levels using The Cancer Genome Atlas (TCGA) data set and Affymetrix data sets using GOBO online analysis.
(a) PAM50 subtypes in TCGA, (b) estrogen receptor (ER) status (GOBO), and (c) PAM50 subtypes (GOBO).
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endocrine therapy is effective in the early stage of
ER-positive breast cancer, recurrence and resistance
to therapy is the principal cause of morbidity and
mortality from breast cancer. The exact process by
which this occurs is complex. Thus, it is crucial to
identify targets with better prognostic and predic-
tive ability to improve the success of endocrine
therapies and prevent breast cancer mortality. The
Oncotype DX recurrence score in current practice
predicts the likelihood of distant recurrence in
tamoxifen-treated patients with node-negative, ER-
positive breast cancer.22 However, like other
signatures for ER-positive cancers, it is predomi-
nantly based on proliferation and does not provide
predictive ability to overcome de novo or acquired
resistance.
Choice of endocrine therapy varies based on the
menopausal status of women. In premenopausal
Figure 4 Kaplan–Meier analysis using The Cancer Genome Atlas (TCGA) data set and Affymetrix data sets using GOBO online analysis.
(a) Overall survival in TCGA (months); (b) 10-year overall survival (OS) as end point for all tumors, estrogen receptor (ER)-positive
tumors, and ER-negative tumors; and (c) 10-year relapse-free survival (RFS)-free survival as end point for all tumors, ER-positive tumors,
ER-positive tamoxifen (Tam)-treated tumors, and ER-negative tumors. The expression analysis was stratified into three quantiles based
on SF3B3 expression; low expression (black), medium expression (light gray), and high expression (dark gray).
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women with hormone receptor-positive disease,
tamoxifen, a selective estrogen receptor modulator,
is considered the standard endocrine therapy of
choice in combination with or without ovarian
suppression/ablation. Recent results of the Adjuvant
Tamoxifen: Longer Against Shorter and the Adju-
vant Tamoxifen Treatment Offer More trials demon-
strated the beneficial effect of extended tamoxifen
therapy in ER-positive breast cancer and provided
an important treatment approach in high-risk young
patients.23,24 However, despite these successes, the
resistance to tamoxifen still remains a problem
which might develop through multiple mechanisms,
including the deregulation of ER pathway and
upregulation of growth factor signaling. This
further switches the tumor pathways to hormone-
independent and nonnuclear/nongenomic ER
activities.25
A growing body of evidence suggests that splicing
factors may provide prognostic and predictive utility
in several cancers including breast cancer.2 In
particular, the identification of mutations in splic-
ing factor genes may present candidates with
prognostic and predictive utility. They also may
serve as excellent therapeutic targets as they regulate
alternative splicing of multiple genes that contribute
to cancer recurrence and resistance to therapies.
Herein, we demonstrated that SF3B3 was
significantly upregulated in tamoxifen-resistant
LCC2 and in fulvestrant-resistant and tamoxifen
cross-resistant LCC9 cell lines, suggesting its
association with resistance to endocrine therapy.
In this study, we also demonstrated that higher
expression of SF3B3 was seen in ER-negative
cancers than in ER-positive cancers. In ER-positive
cancers, consistent with the cell line studies, the
expression of SF3B3 was higher in luminal B tumors
than in luminal A tumors, reiterating the possible
role in aggressive types of ER-positive cancers.
Consistent with the aggressive nature of tumors,
we further showed that higher expression of SF3B3,
but not SF3B1, was significantly associated with
Oncotype DX high-score cases.
To confirm the data observed, we performed
analysis of large publically available gene expres-
sion data sets. Analyses were performed using
TCGA cohorts and GOBO Affymetrix-based data
sets. These analyses confirmed the association of
high SF3B3 expression with high histological grade.
Most importantly, larger data sets, including TCGA
and microarray, further confirmed the significant
correlation of high SF3B3 levels with shorter overall
survival in ER-positive, but not in ER-negative
patients. The association of SF3B3 expression with
poor outcome was even more prominent in node-
positive tumors than in node-negative tumors. An
analysis of relapse-free survival was not possible in
TCGA data set due to the short follow-up period in
this cohort. However, our analysis using GOBO data
set documented that SF3B3 expression was asso-
ciated with shorter overall survival. In GOBO data
set, information about tamoxifen treated was avail-
able on 326 patients. In this subset analysis, high
expression of SF3B3 was associated with poor
outcome (Figure 4). This supports the postulated
association of high SF3B3 expression in tamoxifen
resistance.
SF3B1 was not correlated with relapse-free survi-
val in either ER-positive or ER-negative breast
cancers lacking any prognostic relevance using the
breast cancer data sets, although its mutations have
been identified among the most significantly mu-
tated genes in TCGA data set.5 This suggests that
SF3B1 may not be a major driver in recurrence of
these cancers. SF3B1 and SF3B3 proteins are known
to form a complex that is integral for splicing the
RNAs. Thus the lack of association of SF3B1 with
survival is surprising, and will be a subject of further
studies. Similarly, the role of SF3B3 and SF3B1 in
HER2 and basal subtypes is not clear, as they did not
significantly correlate with relapse-free survival in
these tumors. This may indicate differential regula-
tion of SF3B3 based on the ER status.
The combination of endocrine therapy with other
drugs targeting key molecules involved in endocrine
resistance is the most promising approach to
prevent and/or overcome endocrine resistance and
benefit these breast cancer patients. The spliceo-
some inhibitors targeting SF3B complex may serve
as potential candidates. Several groups have devel-
oped inhibitors targeting spliceosomal pathway to
reduce the cellular growth of cancer cells. Among
them, synthetic analogs, such as spliceostatin A,
Table 1 Multivariable analysis in ER-positive patients for overall
survival (Affymetrix data sets-GOBO)
Variable HR (95% CI) P value*
Low SF3B3 vs high SF3B3 0.6 (0.41–0.89) 0.011
Node negative vs node positive 0.46 (0.33–0.64) 3.838e 06
Grade 3 vs grade 1 or grade 2 1.3 (0.89–1.88) 0.7196
Age Z50 years vs o50 years 1.58 (1.11–2.24) 0.0117
Tumor size Z20mm vs o20mm 1.94 (1.38–2.72) 0.0001
Abbreviations: CI, confidence interval; HR, hazard ratio.
*Pr0.05 is considered as statistically significant.
Table 2 Multivariable analysis in ER-positive patients for
relapse-free survival (Affymetrix data sets-GOBO)
Variable HR (95% CI) P value*
Low SF3B3 vs high SF3B3 0.62 (0.45–0.86) 0.0046
Node negative vs node positive 0.72 (0.54–0.96) 0.0266
Grade 3 vs grade 1 or grade 2 1.09 (0.79–1.5) 0.6127
Age Z50 years vs o50 years 0.81 (0.61–1.09) 0.1634
Tumor size Z20mm vs
o20mm
1.92 (1.45–2.54) 5.388e 06
Abbreviations: CI, confidence interval; HR, hazard ratio.
*Pr0.05 is considered as statistically significant.
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meayamycin, sudemycins, and E7107 are currently
under study.16,26–28 Meayamycin has been found
more potent and stable than its natural compound
FR901464 in various tumor cell lines, including
MCF-7 and MDA-MB231 breast cancer cell lines.29
Sudemycins, analogs of parental compound
FR901464, have also been developed to target SF3b
and shown to modulate alternative splicing in
human tumor xenografts.28,30 E7107 entered
clinical trials as an anticancer agent. However, the
incidence of a few cases of vision loss led to study
discontinuation.31,32 This may be drug specific and
other inhibitors need to be investigated.
In conclusion, our findings suggest a role for the
elevated expression of SF3B3 in poor prognosis and
tamoxifen resistance, leading to recurrence of
ER-positive breast cancer. Confirmation of these
findings could lead to new treatment strategies,
including spliceosome inhibitors to reverse de novo
and acquired tamoxifen resistance. Such therapies
could prevent not only early, but also late recurrence
in ER-positive subtype, which is a major cause of
anxiety in breast cancer survivors.
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